Asia-Pacific Dengue Treatment Market, By Strains (DENV-1, DENV-2, DENV-3, DENV-4, Others), Transmission (Mosquito-to-Human Transmission and Mother-to-Child Transmission), Type (Medication, Supportive Care, Vaccination and Others), Severity (Uncomplicated and Severe), Route of Administration (Oral and Parenteral), Mode of Purchase (Prescription and Over the Counter (OTC)), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (Japan, China, Australia, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2028
Market Analysis and Insights: Asia-Pacific Dengue Treatment Market
The dengue treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 26.3% in the forecast period of 2021 to 2028 and is expected to reach USD 1,941.62 million by 2028. Strategic initiatives by market players and advent of mass vaccination programmes for dengue treatment are likely to be the key drivers for the dengue treatment market.
Dengue is a viral disease transmitted by mosquitoes which has spread rapidly in all WHO (World Health Organization) regions in recent years. The dengue virus is mainly transmitted by female mosquitoes from the genus Aedes aegypti and to a lesser degree from Ae. albopictus. The diseases transmitted by these vector mosquitoes are chikungunya, yellow fever and Zika viruses. Dengue is prevalent in the tropics, induced by precipitation, temperature, relative humidity and unplanned rapid urbanization with local risk variability.
In spite of the controlled steps, the global increase in dengue incidence, along with the increased frequency of localized outbreaks and the potential of aedes species to flourish lead to increase in consumption of the treatment option for dengue treatment and is expected to act as a driver for the dengue treatment market. The cost of dengue treatment are higher as listed in above statement and with more complication related to dengue such as multi organ failure and others can increase the total cost for the therapy results in infected person to avoid proper therapies for dengue treatment thus can act as a restraint for the dengue treatment market. Dengue can be diagnosed traditionally by serological testing but now with the technology upgradation, different ongoing and developed ways are there for virus detection which will create an opportunity for the dengue treatment market. The dengue is a vector borne disease with non-specific drugs such as antipyretic and some antibiotics but the preventive measure and initiatives taken by the different government agencies worldwide is expected to act as a challenge for the dengue treatment market.
The dengue treatment market report provides details of market share, new developments, and impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the dengue treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Dengue Treatment Market Scope and Market Size
The dengue treatment market is segmented on the basis of strains, transmission, type, severity, route of administration, mode of purchase, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of strains, the dengue treatment market is segmented into DENV-1, DENV-2, DENV-3, DENV-4, others. In 2021, DENV-2 segment is dominating the market as this strain is high in prevalence globally which result in higher infection cases of dengue fever.
- On the basis of transmission, the dengue treatment market is segmented into mosquito-to-human transmission and mother-to-child transmission. In 2021, mosquito-to-human transmission segment is dominating in the market as the mosquitoes are the primary vector for the transmission of dengue for the different strains of the virus.
- On the basis of type, the dengue treatment market is segmented into medication, supportive care, vaccination and others. In 2021, medication segment is dominating in the market as variety of drugs used for treating dengue are being used for the management of dengue fever from the very long time.
- On the basis of severity, the dengue treatment market is segmented into uncomplicated and severe. In 2021, uncomplicated segment is dominating in the market as the conversion rate of uncomplicated dengue to severe dengue is less than 5% which is the most important reason that the uncomplicated segment is dominating in the dengue treatment market.
- On the basis of route of administration, the dengue treatment market is segmented into oral and parenteral. In 2021, oral segment is dominating in the market as most of the drugs that are taken to treat the symptoms of dengue are taken orally for pain management and fever management.
- On the basis of mode of purchase, the dengue treatment market is segmented into prescription and over the counter (OTC). In 2021, prescription segment is dominating in the market as the medication and the supportive care is prescribed by the doctors after the confirmation that the patient is infected by the dengue virus and the treatment options consist of antibiotics and other medication which are generally not available as prescribed medication only.
- On the basis of end user, the dengue treatment market is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, home healthcare segment is dominating in the market as the symptoms of dengue can be managed at home using medications such as pain relief and fever management drugs after the diagnosis.
- On the basis of distribution channel, the dengue treatment market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. In 2021, retail pharmacies segment is dominating in the market as after proper diagnosis of dengue, most of the prescriptions by patients are filled in retail pharmacies during the total duration of the treatment cycle of the infection.
Asia-Pacific Dengue Treatment Market Country Level Analysis
Asia-Pacific dengue treatment market is analysed and market size information is provided by the country, strains, transmission, type, severity, route of administration, mode of purchase, end user and distribution channel as referenced above.
The countries covered in the Asia-Pacific dengue treatment market report are the Japan, China, Australia, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam and rest of Asia-Pacific.
Asia-Pacific is expected to grow with the highest CAGR in the forecast period as in the Asia-Pacific’s countries, the demand for dengue treatment products is increasing very rapidly with the urbanization and laboratory automation. China is expected to dominate in the Asia-Pacific dengue treatment market as China is one of the leading countries to inculcate dengue treatment market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Necessity of Dengue Treatment in Urban Areas and the Strategic Initiatives by Market Players are is creating new opportunities for Players in the Dengue Treatment Market
The dengue treatment market also provides you with detailed market analysis for every country growth in particular industry with dengue treatment sales, impact of advancement in the dengue treatment and changes in regulatory scenarios with their support for the dengue treatment market. The data is available for historic period 2011 to 2019.
Competitive Landscape and Dengue Treatment Market Share Analysis
The dengue treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to dengue treatment market.
The major companies which are dealing in the Asia-Pacific dengue treatment market report are Takeda Pharmaceutical Company Limited, Sanofi, GlaxoSmithKline plc, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Baxter, Viatris Inc. among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The strategic initiatives by market players with capital investment for dengue research are bridging the gap between dengue and its treatment in the dengue treatment market.
For instance,
- In November 2020, Viatris Inc. was launched as a combination of two Mylan N.V. and Pfizer Upjohn business. This combination of the two will focus on improving patient health. Viatris Inc. has the scientific production and distribution expertise with proven medical, regulatory and global commercial capabilities to provide high-quality medicines to patients in more than 165 countries and territories. This launch of a new company will increase the revenue of the company in near future.
Collaboration, joint ventures and other strategies by the market players is enhancing the company market in the dengue treatment market which also provides the benefit for organisation to improve their offering for dengue treatment market.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC DENGUE TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 STRAINS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
5 PIPELINE ANALYSIS
6 ASIA-PACIFIC DENGUE TREATMENT MARKET: REGULATIONS
6.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT
6.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT
6.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK
6.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE
6.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK
7 CLINICAL STUDIES FOR DENGUE TREATMENT PRODUCTS.
7.1 SYNTHETIC DRUGS
7.2 BIOMARKER
7.3 DIRECT ACTING ANTIVIRAL DRUGS
8 EPIDEMIOLOGY
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASING INCIDENCE IN DENGUE CASES
9.1.2 ADVENT OF VACCINATION PROGRAMS
9.1.3 INCREASE IN RESEARCH AND DEVELOPMENT FUNDING
9.1.4 ROLE OF IGM AND IGG ANTIBODIES IN DENGUE
9.1.5 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES
9.2 RESTRAINTS
9.2.1 HIGH COST OF TREATMENT
9.2.2 DEARTH AWARENESS ABOUT THE SYMPTOMS OF DENGUE
9.2.3 LACK OR INSUFFICIENT HEALTHCARE INFRASTRUCTURE
9.3 OPPORTUNITIES
9.3.1 NEED FOR DENGUE TREATMENT IN URBAN AREAS
9.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
9.3.3 TECHNOLOGICAL ADVANCEMENT IN DENGUE VIRUS DETECTION
9.3.4 INCREASE IN ASIA-PACIFIC TRAVEL AND RELATION WITH DENGUE
9.4 CHALLENGES
9.4.1 PRESENCE OF PREVENTIVE MEASURES FOR DENGUE AND IT’S SPREAD
9.4.2 CHALLENGES IN DETECTION ASSAY FOR DENGUE
9.4.3 ALTERNATIVES FOR DENGUE TREATMENT
10 IMPACT OF COVID-19 ON ASIA-PACIFIC DENGUE TREATMENT MARKET
10.1 IMPACT ON PRICE
10.2 IMPACT ON DEMAND
10.3 IMPACT ON SUPPLY CHAIN
10.4 STRATEGIC DECISION BY MANUFACTURERS
10.5 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
10.6 CONCLUSION
11 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY STRAINS
11.1 OVERVIEW
11.2 DENV-3
11.3 DENV-2
11.4 DENV-1
11.5 DENV-4
11.6 OTHERS
12 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY TRANSMISSION
12.1 OVERVIEW
12.2 MOSQUITO-TO-HUMAN TRANSMISSION
12.3 MOTHER-TO-CHILD- TRANSMISSION
12.4 OTHERS
13 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY TYPE
13.1 OVERVIEW
13.2 MEDICATION
13.2.1 ACETAMINOPHEN
13.2.2 ANTIBIOTICS
13.2.2.1 Ciprofloxacin
13.2.2.2 Chloramphenicol
13.2.2.3 Ceftriaxone
13.2.2.4 Ofloxacin
13.2.2.5 Others
13.2.3 IMMUNOGLOBULINS
13.2.4 CORTICOSTEROIDS
13.2.5 ANTI-VIRALS
13.2.6 OTHERS
13.3 SUPPORTIVE CARE
13.4 VACCINATION
13.4.1 DENGVAXIA (CYD-TDV)
13.4.2 DENVAX (TAK-003)
13.4.3 TETRAVAX-DV
13.4.4 TDEN PIV
13.5 OTHERS
14 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY SEVERITY
14.1 OVERVIEW
14.2 UNCOMPLICATED
14.3 SEVERE
15 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLET
15.2.2 CAPSULES
15.2.3 OTHERS
15.3 PARENTERAL
15.3.1 INTRAVENOUS
15.3.2 SUBCUTANEOUS
15.3.3 OTHERS
16 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY MODE OF PURCHASE
16.1 OVERVIEW
16.2 PRESCRIPTION
16.3 OVER THE COUNTER (OTC)
17 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY END USER
17.1 OVERVIEW
17.2 HOME HEALTHCARE
17.3 HOSPITALS
17.4 SPECIALTY CLINICS
17.5 OTHERS
18 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 RETAIL PHARMACIES
18.3 HOSPITAL PHARMACY
18.4 ONLINE PHARMACY
18.5 OTHERS
19 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY GEOGRAPHY
19.1 ASIA-PACIFIC
19.1.1 MALAYSIA
19.1.2 PHILIPPINES
19.1.3 VIETNAM
19.1.4 INDONESIA
19.1.5 INDIA
19.1.6 THAILAND
19.1.7 SINGAPORE
19.1.8 AUSTRALIA
19.1.9 CHINA
19.1.10 JAPAN
19.1.11 SOUTH KOREA
19.1.12 REST OF ASIA-PACIFIC
20 ASIA-PACIFIC DENGUE TREATMENT MARKET, COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
21 SWOT ANALYSIS
22 COMPANY PROFILE
22.1 VIATRIS INC.
22.1.1 COMPANY SNAPSHOT
22.1.2 COMPANY SHARE ANALYSIS
22.1.3 PRODUCT PORTFOLIO
22.1.4 RECENT DEVELOPMENT
22.2 PFIZER INC.
22.2.1 COMPANY SNAPSHOT
22.2.2 REVENUE ANALYSIS
22.2.3 COMPANY SHARE ANALYSIS
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPMENTS
22.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
22.3.1 COMPANY SNAPSHOT
22.3.2 REVENUE ANALYSIS
22.3.3 COMPANY SHARE ANALYSIS
22.3.4 PRODUCT PORTFOLIO
22.3.5 RECENT DEVELOPMENT
22.4 PERRIGO COMPANY PLC
22.4.1 COMPANY SNAPSHOT
22.4.2 REVENUE ANALYSIS
22.4.3 COMPANY SHARE ANALYSIS
22.4.4 PRODUCT PORTFOLIO
22.4.5 RECENT DEVELOPMENTS
22.5 GLAXOSMITHKLINE PLC
22.5.1 COMPANY SNAPSHOT
22.5.2 REVENUE ANALYSIS
22.5.3 COMPANY SHARE ANALYSIS
22.5.4 PRODUCT PORTFOLIO
22.5.5 RECENT DEVELOPMENT
22.6 DR. REDDY’S LABORATORIES LTD.
22.6.1 COMPANY SNAPSHOT
22.6.2 REVENUE ANALYSIS
22.6.3 PRODUCT PORTFOLIO
22.6.4 RECENT DEVELOPMENT
22.7 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA)
22.7.1 COMPANY SNAPSHOT
22.7.2 REVENUE ANALYSIS
22.7.3 PRODUCT PORTFOLIO
22.7.4 RECENT DEVELOPMENTS
22.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
22.8.1 COMPANY SNAPSHOT
22.8.2 REVENUE ANALYSIS
22.8.3 PRODUCT PORTFOLIO
22.8.4 RECENT DEVELOPMENTS
22.9 ABIVAX
22.9.1 COMPANY SNAPSHOT
22.9.2 PRODUCT PORTFOLIO
22.9.3 RECENT DEVELOPMENTS
22.1 AUROBINDO PHARMA
22.10.1 COMPANY SNAPSHOT
22.10.2 REVENUE ANALYSIS
22.10.3 PRODUCT PORTFOLIO
22.10.4 RECENT DEVELOPMENTS
22.11 BAXTER
22.11.1 COMPANY SNAPSHOT
22.11.2 REVENUE ANALYSIS
22.11.3 PRODUCT PORTFOLIO
22.11.4 RECENT DEVELOPMENT
22.12 EMERGEX VACCINES
22.12.1 COMPANY SNAPSHOT
22.12.2 PRODUCT PORTFOLIO
22.12.3 RECENT DEVELOPMENTS
22.13 HIKMA PHARMACEUTICALS PLC
22.13.1 COMPANY SNAPSHOT
22.13.2 REVENUE ANALYSIS
22.13.3 PRODUCT PORTFOLIO
22.13.4 RECENT DEVELOPMENT
22.14 SANOFI
22.14.1 COMPANY SNAPSHOT
22.14.2 REVENUE ANALYSIS
22.14.3 PRODUCT PORTFOLIO
22.14.4 RECENT DEVELOPMENTS
22.15 TAKEDA PHARMACEUTICAL COMPANY LIMITED
22.15.1 COMPANY SNAPSHOT
22.15.2 REVENUE ANALYSIS
22.15.3 PRODUCT PORTFOLIO
22.15.4 RECENT DEVELOPMENTS
23 QUESTIONNAIRE
24 RELATED REPORTS
Tabellenverzeichnis
LIST OF TABLES
TABLE 1 ASIA-PACIFIC DENGUE TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION
TABLE 3 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY STRAINS 2019-2028 (USD MILLION)
TABLE 4 ASIA-PACIFIC DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 ASIA-PACIFIC DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 ASIA-PACIFIC DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC MOSQUITO-TO-HUMAN TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC MOTHER-TO-CHILD TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 16 ASIA-PACIFIC ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC SUPPORTIVE CARE IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 19 ASIA-PACIFIC VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 21 ASIA-PACIFIC OTHERS IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 22 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY SEVERITY 2019-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC UNCOMPLICATED IN DENGUE TREATMENT MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC SEVERE IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION
TABLE 27 ASIA-PACIFIC ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION
TABLE 29 ASIA-PACIFIC PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC PRESCRIPTION IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION
TABLE 32 ASIA-PACIFIC OVER THE COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION
TABLE 33 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 34 ASIA-PACIFIC HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 35 ASIA-PACIFIC HOSPITALS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 36 ASIA-PACIFIC SPECIALTY CLINICS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 37 ASIA-PACIFIC OTHERS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 38 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 ASIA-PACIFIC DIRECT TENDER IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 40 ASIA-PACIFIC HOSPITAL PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 41 ASIA-PACIFIC ONLINE PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 42 ASIA-PACIFIC HOSPITALS IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 43 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 44 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 45 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 46 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 ASIA-PACIFIC MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 ASIA-PACIFIC ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 ASIA-PACIFIC OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 ASIA-PACIFIC VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 52 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 53 ASIA-PACIFIC ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 54 ASIA-PACIFIC PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 55 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 56 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 57 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 58 MALAYSIA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 59 MALAYSIA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 60 MALAYSIA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 MALAYSIA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 MALAYSIA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 MALAYSIA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 MALAYSIA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 MALAYSIA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 66 MALAYSIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 67 MALAYSIA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 68 MALAYSIA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 69 MALAYSIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 70 MALAYSIA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 71 MALAYSIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 72 PHILIPPINES DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 73 PHILIPPINES DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 74 PHILIPPINES DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 PHILIPPINES MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 PHILIPPINES ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 PHILIPPINES OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 PHILIPPINES VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 79 PHILIPPINES DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 80 PHILIPPINES DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 PHILIPPINES ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 82 PHILIPPINES PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 83 PHILIPPINES DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 84 PHILIPPINES DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 85 PHILIPPINES DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 86 VIETNAM DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 87 VIETNAM DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 88 VIETNAM DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 VIETNAM MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 VIETNAM ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 VIETNAM OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 VIETNAM VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 VIETNAM DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 94 VIETNAM DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 95 VIETNAM ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 VIETNAM PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 VIETNAM DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 98 VIETNAM DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 VIETNAM DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 100 INDONESIA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 101 INDONESIA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 102 INDONESIA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 103 INDONESIA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 104 INDONESIA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 105 INDONESIA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 106 INDONESIA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 107 INDONESIA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 108 INDONESIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 109 INDONESIA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 110 INDONESIA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 111 INDONESIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 112 INDONESIA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 113 INDONESIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 114 INDIA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 115 INDIA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 116 INDIA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 117 INDIA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 118 INDIA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 119 INDIA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 120 INDIA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 121 INDIA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 122 INDIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 123 INDIA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 124 INDIA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 125 INDIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 126 INDIA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 127 INDIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 128 THAILAND DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 129 THAILAND DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 130 THAILAND DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 THAILAND MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 THAILAND ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 133 THAILAND OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 134 THAILAND VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 135 THAILAND DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 136 THAILAND DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 137 THAILAND ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 138 THAILAND PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 139 THAILAND DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 140 THAILAND DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 141 THAILAND DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 142 SINGAPORE DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 143 SINGAPORE DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 144 SINGAPORE DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 145 SINGAPORE MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 146 SINGAPORE ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 147 SINGAPORE OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 148 SINGAPORE VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 149 SINGAPORE DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 150 SINGAPORE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 151 SINGAPORE ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 152 SINGAPORE PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 153 SINGAPORE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 154 SINGAPORE DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 155 SINGAPORE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 156 AUSTRALIA E DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 157 AUSTRALIA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 158 AUSTRALIA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 159 AUSTRALIA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 160 AUSTRALIA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 161 AUSTRALIA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 162 AUSTRALIA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 163 AUSTRALIA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 164 AUSTRALIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 165 AUSTRALIA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 166 AUSTRALIA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 167 AUSTRALIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 168 AUSTRALIA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 169 AUSTRALIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 170 CHINA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 171 CHINA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 172 CHINA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 173 CHINA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 174 CHINA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 175 CHINA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 176 CHINA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 177 CHINA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 178 CHINA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 179 CHINA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 180 CHINA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 181 CHINA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 182 CHINA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 183 CHINA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 184 JAPAN DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 185 JAPAN DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 186 JAPAN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 187 JAPAN MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 188 JAPAN ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 189 JAPAN OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 190 JAPAN VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 191 JAPAN DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 192 JAPAN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 193 JAPAN ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 194 JAPAN PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 195 JAPAN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 196 JAPAN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 197 JAPAN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 198 SOUTH KOREA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 199 SOUTH KOREA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 200 SOUTH KOREA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 201 SOUTH KOREA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 202 SOUTH KOREA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 203 SOUTH KOREA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 204 SOUTH KOREA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 205 SOUTH KOREA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 206 SOUTH KOREA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 207 SOUTH KOREA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 208 SOUTH KOREA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 209 SOUTH KOREA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 210 SOUTH KOREA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 211 SOUTH KOREA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 212 REST OF ASIA-PACIFIC DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
Abbildungsverzeichnis
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC DENGUE TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC DENGUE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC DENGUE TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC DENGUE TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC DENGUE TREATMENT MARKET: MARKET END USER GRID
FIGURE 10 ASIA-PACIFIC DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 ASIA-PACIFIC DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 12 INCREASING INCIDENCE OF DENGUE CASES AND ADVENT OF VACCINATION PROGRAMS ARE DRIVING THE ASIA-PACIFIC DENGUE TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 FUNGAL DENGUE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC DENGUE TREATMENT MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF ASIA-PACIFIC DENGUE TREATMENT MARKET
FIGURE 15 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY STRAINS, 2020
FIGURE 16 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY STRAINS, 2020-2028 (USD MILLION)
FIGURE 17 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2021-2028)
FIGURE 18 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE
FIGURE 19 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY TRANSMISSION, 2020
FIGURE 20 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY TRANSMISSION 2020-2028 (USD MILLION)
FIGURE 21 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY TRANSMISSION, CAGR (2021-2028)
FIGURE 22 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY TRANSMISSION, LIFELINE CURVE
FIGURE 23 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY TYPE, 2020
FIGURE 24 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 25 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY TYPE, CAGR (2020-2028)
FIGURE 26 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 27 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY SEVERITY, 2020
FIGURE 28 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY SEVERITY , 2020-2028 (USD MILLION)
FIGURE 29 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2021-2028).
FIGURE 30 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 33 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 34 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020
FIGURE 36 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020-2028 (USD MILLION)
FIGURE 37 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2020-2028)
FIGURE 38 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY END USER, 2020
FIGURE 40 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 41 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY END USER, CAGR (2020-2028)
FIGURE 42 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 44 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 45 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 46 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 ASIA-PACIFIC DENGUE TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 48 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 49 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 51 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY STRAINS (2021-2028)
FIGURE 52 ASIA-PACIFIC DENGUE TREATMENT MARKET: COMPANY SHARE 2020 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
